With the help of directed evolution, scientists inch closer to developing viral vectors that can cross the human blood-brain barrier to deliver gene therapy.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

Technologies such as noninvasive brain stimulation and virtual reality gaming offer insights into how dreams arise and what functions they might serve.

The scientific community said goodbye to Sydney Brenner, Paul Greengard, Patricia Bath, and a number of other leading researchers this year.

An advisory committee for the BRAIN Initiative says that to fully fund the goals of the neuroscience research program, taxpayers should fork over $4.5 billion.

The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.

From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.

Receptors that bind the active ingredient in marijuana may be novel therapeutic targets in autoimmune disease, but contested evidence for their presence on neurons could hamper drug development

Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two

Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two